Drug Profile


Alternative Names: MK-0457; VX-680

Latest Information Update: 20 Aug 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck & Co
  • Class Antineoplastics; Piperazines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Haematological malignancies; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 03 Jun 2008 Preclinical pharmacodynamics data of combination of tozasertib with vorinostat in Chronic myeloid leukaemia presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 20 Nov 2007 Merck & Co suspends patient enrollment in clinical trials of tozasertib until full analysis of clinical data can be conducted
  • 04 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the adverse events and Cancer therapeutic trials and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top